ABX-CRO advanced pharmaceutical services Forschungsgesellschaft

EPHORAN Multi-Imaging Solutions is a Contract Research Organization providing imaging expertise and knowledge to study, develop and promote the application of imaging technologies in preclinical drug research and development.

EPHORAN provides the opportunity to apply a translational pharmacological approach in drug R&D, evaluating in animal models a molecular-based proof of biological activity and mechanism of action, and translating it into the clinical setting. All the Techniques extensively employed in the clinical setting(e.g. PET, CT, SPECT, MRI, US and in Optical Imaging, both visible light and Near Infra Red) are available.

EPHORAN fosters the development of diagnostic tools, reagents and methodologies for experimental imaging and makes the drug development faster and more cost effective. Pharmaceutical companies will take advantage from its preclinical imaging technologies to carry on more effectively their R&D projects in different therapeutic such as oncology, cardiovascular and CNS. The application of Imaging techniques allows a significant reduction of the time-to-market of novel compounds. Other users that will benefit from access to Ephoran’s services are Researchers from academic and research institution.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

Explicyte is a family brand of specialty preclinical services launched by ImmuSmol, a bordeaux-based company. The first brand, Explicyte Immune-Oncology offers preclinical contract research services in immuno-oncology.

Explicyte Immuno-Oncology currently offers to test innovative cancer immunotherapies in vivo, using syngeneic mouse tumor models treated with immune checkpoint inhibitors (eg. anti-CTLA-4 and anti-PD1/PD-L1 antibodies). In addition, Explicyte is setting up an in vitro platform for the identification and optimization of novel immunomodulators. Equipped with high-content analysis technologies, the platform focuses on live phenotypic screening in co-cultures of immune and cancer cells, as well as molecular cell-based assays for the assessment of immune checkpoint inhibitors.

The IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto - is a private non-profit association of public utility, founded in 1989 under the aegis of the University of Porto.

The Effective Associates of IPATIMUP are: Municipal Council of Porto, the Commission of Coordination and Regional Development of the North Region, the Portuguese Red Cross, the Luso-American Foundation for Development, the National Institute of Health Dr. Ricardo Jorge/Center of Medical Genetics Dr. Jacinto de Magalhães, the Portuguese League Against Cancer, the Bial Foundation and the University of Porto.
The Adherent Associates are: the Faculty of Medicine, the Faculty of Sciences, the Faculty of Nutrition, the Faculty of Dental Medicine, the Faculty of Pharmacy and the Instituto of Biomedical Sciences Abel Salazar, all from the University of Porto; the Hospital S. João and the Portuguese Institute of Oncology .

The IPATIMUP was one of the four first ones Associated Laboratories created by the Ministry of Science and Higher Education in 2000. It is installed in a building with 4.000m2 in Polo 2 (Asprela) of the University of Porto.

Physiomics plc combines systems biology, PKPD and cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

Virtual Tumour is a flexible in-silico model of cancer that has been used successfully to simulate a wide range of cancer types, cell lines, molecular targets and combinations of pharmaceutical and radiation therapy. The Company has worked in the small molecule as well as the biological space and has experience of traditional chemo, targeted chemo and immuno-therapies.

The Company has completed over 50 projects with a range of commercial and academic clients including Lilly, Merck Inc, Merck KGaA, Bayer Technology Services, Sareum, ValiRx, Cancer Research Technologies, Cyclacel, Innovate UK, NIH, Oxford University and Cancer Research Technology.

The Company is based in Oxford and has close ties to the University and Hospital located there.